New standards of care for treatment of diffuse large B‐cell lymphoma-Reference-Cited by-同舟云学术

New standards of care for treatment of diffuse large B‐cell lymphoma

Published:2024-01-22 Issue:4 Volume:204 Page:1132-1134
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Abeyakoon Chathuri¹²³^ORCID,Gregory Gareth P.¹²^ORCID

Affiliation:

1. Lymphoma Research Group School of Clinical Sciences at Monash Health, Monash University Clayton Victoria Australia

2. Monash Haematology, Monash Health Clayton Victoria Australia

3. Department of Medical Oncology and Haematology Princess Margaret Hospital Toronto Ontario Canada

Abstract

Treatment of newly diagnosed diffuse large B‐cell lymphoma with rituximab and CHOP (R‐CHOP) has been largely unchanged for the last two decades. The Guideline by Fox et al. provides new evidence‐based therapeutic strategies informed by positive results of randomised clinical trials.Commentary on: Fox et al. The management of newly diagnosed large B‐cell lymphoma: A British Society for Haematology Guideline. Br J Haematol 2024; 204:1178‐1192.

Funder

Victorian Cancer Agency

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19295

Reference9 articles.

1. The management of newly‐diagnosed large B‐cell lymphoma: a British Society for Haematology Guideline;Fox C;Br J Haematol,2024

2. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

3. Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014

4. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

5. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma